The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 22, 2009
Filed:
Aug. 21, 2003
Nobuhiko Fushimi, Hotaka-machi, JP;
Kazuo Shimizu, Hotaka-machi, JP;
Shigeru Yonekubo, Hotaka-machi, JP;
Hirotaka Teranishi, Hotaka-machi, JP;
Masaki Tomae, Hotaka-machi, JP;
Masayuki Isaji, Hotaka-machi, JP;
Nobuhiko Fushimi, Hotaka-machi, JP;
Kazuo Shimizu, Hotaka-machi, JP;
Shigeru Yonekubo, Hotaka-machi, JP;
Hirotaka Teranishi, Hotaka-machi, JP;
Masaki Tomae, Hotaka-machi, JP;
Masayuki Isaji, Hotaka-machi, JP;
Kissei Pharmaceutical Co., Ltd., Nagano, JP;
Abstract
The present invention provides pyrazole derivatives represented by the general formula: wherein Rrepresents H, an optionally substituted Calkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted Calkyl group etc.; Rrepresents H, a halogen atom, OH, an optionally substituted Calkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted Calkylene group etc.; Z represents —R, —CORetc. in which Rrepresents an optionally substituted Calkyl group etc.; and Rrepresents an optionally substituted Calkyl group etc.; Rrepresents H, an optionally substituted Calkyl group etc.; and R, Rand Rrepresent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.